• Twitter
  • LinkedIn
  • RSS
InterveXion Therapeutics
  • About Us
    • Overview
    • Management Team
    • Financial Conflict of Interest
  • Research & Development
    • Anti-Methamphetamine Products
    • Intellectual Property
    • Methamphetamine Use Disorder
  • Publications
    • Recent Publications
    • Anti-Methamphetamine Monoclonal Antibody
    • METH Vaccine
    • Anti-Phencyclidine Monoclonal Antibody
    • Review Articles
  • Contact Us
  • News
Select Page

InterveXion Therapeutics Awarded Federal Grant to Fund Phase 2 Study for Methamphetamine Use Disorder

Oct 4, 2021 | Anti-METH antibody, IXT-m200, General News, Grants

Grant fully funds clinical trial, to be called “OUTLAST”, which will initiate in early 2022 LITTLE ROCK, AR, USA, October 4, 2021 /EINPresswire.com/ — InterveXion Therapeutics, a clinical-stage biopharmaceutical company, today announced the award of additional...

InterveXion Enrolls First Patient in Meth-OD, a Phase 2 Study of IXT-m200 in Methamphetamine Overdose

Sep 21, 2021 | Anti-METH antibody, IXT-m200, General News

LITTLE ROCK, AR, USA, September 20, 2021 – InterveXion Therapeutics, a clinical-stage biopharmaceutical company, today announced the enrollment of the first patient in Meth-OD, a Phase 2 study of the first-in-class anti-methamphetamine antibody IXT-m200 in...

InterveXion Announces Positive Data in Phase 2 Study of IXT-m200 in Participants with Methamphetamine Use Disorder

Apr 19, 2021 | Anti-METH antibody, IXT-m200, General News

IXT-m200 produced significant changes in primary endpoint of methamphetamine pharmacokinetics, with favorable data for secondary endpoints and safety LITTLE ROCK, AR, USA, April 19, 2021 – InterveXion Therapeutics, a private clinical-stage biopharmaceutical...

InterveXion Therapeutics Awarded Federal Grant to Fund Phase 2 Study for Methamphetamine Overdose

Oct 5, 2020 | Anti-METH antibody, IXT-m200, General News, Grants

“Meth-OD” trial will be first known clinical trial specifically for patients suffering from methamphetamine overdose LITTLE ROCK, ARKANSAS, USA, October 5, 2020 /EINPresswire.com/ — InterveXion Therapeutics, a clinical-stage biopharmaceutical...

Misuse of methamphetamine remains an extremely serious problem in the US.

Jan 10, 2020 | General News, METH in the news

The misuse of methamphetamine, a highly addictive stimulant remains an extremely serious problem in the United States. Overdose deaths from meth are on the rise, caused in part by dealers who mix it with dangerous synthetic opioid fentanyl. Source: Overview | National...

A New Drug Scourge: Deaths Involving Meth Are Rising Fast – The New York Times

Dec 20, 2019 | General News, METH in the news

Source: A New Drug Scourge: Deaths Involving Meth Are Rising Fast – The New York Times
« Older Entries

Recent Posts

  • InterveXion Therapeutics Awarded Federal Grant to Fund Phase 2 Study for Methamphetamine Use Disorder
  • InterveXion Enrolls First Patient in Meth-OD, a Phase 2 Study of IXT-m200 in Methamphetamine Overdose
  • InterveXion Announces Positive Data in Phase 2 Study of IXT-m200 in Participants with Methamphetamine Use Disorder
  • InterveXion Therapeutics Awarded Federal Grant to Fund Phase 2 Study for Methamphetamine Overdose
  • InterveXion Therapeutics Awarded Federal Grant to Fund Ongoing Development Program for IXT-m200 for Methamphetamine Use Disorder

Recent Comments

    Archives

    • October 2021
    • September 2021
    • April 2021
    • October 2020
    • May 2020
    • February 2020
    • January 2020
    • December 2019
    • November 2019
    • August 2019
    • July 2019
    • June 2019
    • May 2019
    • April 2019
    • February 2019
    • January 2019
    • December 2018
    • November 2018
    • May 2018
    • January 2018
    • October 2017
    • June 2017
    • January 2016
    • January 2015
    • November 2014
    • February 2014
    • August 2013
    • July 2013
    • December 2012
    • November 2012
    • May 2012
    • April 2012
    • July 2011
    • April 2011
    • October 2009
    • September 2009
    • March 2005
    • January 2005

    Categories

    • Anti-METH antibody, IXT-m200
    • Anti-METH Vaccine
    • Anti-PCP ch-mAb6B5
    • General News
    • Grants
    • METH in the news
    • Uncategorized

    Meta

    • Log in
    • Entries RSS
    • Comments RSS
    • WordPress.org
    • Twitter
    • LinkedIn
    • RSS
    © 2017 Intervexion